Treatment of hyperlipidemia after heart transplantation and rationale for the heart transplant lipid registry

American Journal of Cardiology

Volumn 78, Issue 5, 1996, Pages 532-535

  Ballantyne, Christie M ^a   Bourge, Robert C ^a   Domalik, Leslie J ^a   Eisen, Howie J ^a   Fishbein, Daniel P ^a   Kubo, Spencer H ^a   Lake, Kathleen D ^a   Radovancevic, Branislav ^a   Taylor, David O ^a   Ventura, Hector O ^a   Yancy Jr , Clyde W ^a   Young, James B ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG DERIVATIVE; HYPOCHOLESTEROLEMIC AGENT; MEVINOLIN; PRAVASTATIN; SIMVASTATIN;

HEART TRANSPLANTATION; HUMAN; HYPERLIPIDEMIA; POSTOPERATIVE COMPLICATION; REGISTER; REVIEW; TREATMENT OUTCOME;

ANTICHOLESTEREMIC AGENTS; HEART TRANSPLANTATION; HUMANS; HYPERLIPIDEMIAS; LOVASTATIN; POSTOPERATIVE COMPLICATIONS; PRAVASTATIN; REGISTRIES; SIMVASTATIN; TREATMENT OUTCOME;

EID: 10644219635     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9149(96)00358-X     Document Type: Article

References (34)

1. Hosenpud J, Novick RJ, Breen TJ, Keck B, Daily P. The registration of the international society for heart and lung transplantation: twelfth official report. J Heart Lung Transplant 1995;14:805-815.
2. Uretsky BF, Murali S, Reddy PS, Rabin B, Lee A, Griffith BP, Hardesty RL, Trento A, Bahnson HT. Development of coronary artery disease in cardiac transplant patients receiving immunosuppressive therapy with cyclosporine and prednisone. Circulation 1987;76:827-834.
3. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383-1389.
4. Gotto AM. Lipid lowering, regression, and coronary events. Circulation 1995;92:646-656.
5. National Cholesterol Education Program. Second report of the expert panel on detections, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel II) Circulation 1994;89:1329-1445.
6. Ballantyne CM, Jones PH, Payton-Ross C, Patsch W, Short HD, Noon GP, Gotto AM, DeBakey ME, Young JB. Hyperlipidemia following heart transplantation: natural history and intervention with mevinolin (lovastatin). Transp Proc 1987;19(5):60-62.
7. Keogh A, Simons L, Spratt P, Esmore D, Chang V, Hickie J, Baron D. Hyperlipidemia after heart transplantation. J Heart Lung Transplant 1988;7:171-175.
8. Ballantyne CM, Radovancevic B, Farmer JA, Frazier OH, Chandler L, Payton-Ross C, Cocanougher B, Jones PH, Young JB, Gotto AM. Hyperlipidemia after heart transplantation: report of a 6-year experience, with treatment recommendations. J Am Col Cardiol 1992;19:1315-1321.
9. Hess ML, Hastillo A, Mohanakumar T, Cowley MJ, Vetrovac G, Szentpetery S, Wolfgang TC, Lower RR. Accelerated atherosclerosis in cardiac transplantation: role of cytotoxic B-cell antibodies and hyperlipidemia. Circulation 1983;68:II-94-101.
10. Eich D, Thompson JA, Ko D, Hastillo A, Lower R, Katz S, Katz M, Hess ML. Hypercholesterolemia in long-term survivors of heart transplantation: An early marker of accelerated coronary artery disease. J Heart Lung Transplant 1991;10:45-49.
11. Gao S-Z, Schroeder JS, Alderman EL, Hunt SA, Silverman JF, Wiederhold V, Stinson EB. Clinical and laboratory correlates of accelerated coronary artery disease in the cardiac transplant patient. Circulation 1987;76:V-56-61.
12. Cocanougher B, Ballantyne CM, Pollack MS, Payton-Ross C, Lowry R, Kleiman NS, Farmer JA, Noon GP, Short HD, Young JB. Degree of HLA mismatch as a predictor of death from allograft arteriopathy after heart transplant. Transp Proc 1993;25:233-236.
13. Mehra MR, Ventura HO, Chambers R, Collins TJ, Ramee SR, Kates MA, Smart FW, Stapleton DD. Predictive model to assess risk for cardiac allograft vasculopathy: an intravascular ultrasound study. J Am Coll Cardiol 1995;26:1537-1544.
14. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol Education Program (NCEP ) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). JAMA 1993;269:3015-3023.
15. Kobashigawa JA, Katznelson S, Laks H, Johnson JA, Yeatman L, Wang XM, Chia D, Terasaki PI, Sabad A, Cogert GA, Trosian K, Hamilton MA, Moriguchi JD, Kawata N, Hage A, Drinkwater DC, Stevenson LW. Effect of pravastatin on outcomes after cardiac transplantation. N Engl J Med 1995;333:621-627.
16. Cults JL, Bankhurst AD. Reversal of lovastatin-mediated inhibition of natural killer cell cytotoxicity by interleukin 2. J Cell Physiol 1990;145:244-252.
17. Awni WM, Heim-Duthoy K, Kasiske BL. Impact of lipoproteins on cyclosporine pharmacokinetics and biological activity in transplant patients. Transp Proc 1990;22:1193-1196.
18. Meiser BM, Wenke K, Thiery J, Wolf S, Devens CH, Seidel D, Hammer C, Billingham ME, Reichart B. Simvastatin decreases accelerated graft vessel disease after heart transplantation in an animal model. Transp Proc 1993;25:2077-2079.
19. Vincent TS, Wulfert E, Merler E. Inhibition of growth factor signaling pathways by lovastatin. Biochem Biophy Res Comm 1991;180:1284-1289.
20. Norman DJ, Illingworth DR, Munson J, Hosenpud J. Myolysis and acute renal failure in a heart-transplant recipient receiving lovastatin. N Engl J Med 1988;318:46-47.
21. Kobashigawa JA, Murphy FL, Stevenson LW, Moriguchi JD, Kawata N, Kamjoo P, Brownneld E, Wilmarth J, Leonard L, Chuck C, Drinkwater D, Laks H. Low-dose lovastatin safely lowers cholesterol after cardiac transplantation. Circulation 1990;82:IV-281-283.
22. Bradford RH, Shear CL, Chremos AN et al. Expanded clinical evaluation of lovastatin (EXCEL) study results: I. Efficacy in modifying plasma lipoproteins and adverse event profile in 8245 patients with moderate hypercholesterolemia. Arch Intern Med 1991;151:43-49.
23. Kuo PC, Kirshenbaum JM, Gordon J, Laffel G, Young P, DiSesa VJ, Mudge GH, Vaughan DE. Lovastatin therapy for hypercholesterolemia in cardiac transplant recipients. Am J Cardiol 1989;64:631-635.
24. Peters JR, Kubo SH, Olivari MT, Knutson KR, Hunninghake DB. Treatment of hyperlipidemia in heart transplant recipients with gemfibrozil ± lovastatin. Am J Cardiol 1993;71:1485-1488.
25. Anguita M, Alonso-Pulpon L, Arizon JM, Cavero MA, Valles F, Segovia J, Ferez-Jimenez F, Crespo M, Concha M. Comparison of the effectiveness of lovastatin therapy for hypercholesterolemia after heart transplantation between patients with and without pretransplant atherosclerotic coronary artery disease. Am J Cardiol 1994;74:776-779.
26. Hidalgo L, Zambrana JL, Blanco-Molina A, Lopez-Granados A, Concha M, Casares J, Ferez-Jimenez F. Lovastatin versus bezanbrate for hyperlipemia treatment after heart transplantation. J Heart Lung Transplant 1995;14:461-467.
27. Barbir M, Rose M, Kushwaha S, Akl S, Mitchell A, Yacoub M. Low-dose simvastatin for the treatment of hypercholesterolemia in recipients of cardiac transplantation. Int J Cardiol 1991;33:241-246.
28. Vanhaecke J, Van Cleemput J, Van Lierde J, Daenen W, De Geest H. Safety and efficacy of low dose simvastatin in cardiac transplant recipients treated with cyclosporine. Transplantation 1994;58:42-45.
29. Campana C, Iacona I, Regazzi MB, Gavazzi A, Perani G, Raddato V, Montemartini C, Vigano M. Efficacy and pharmacokinetics of simvastatin in heart transplant recipients. Ann Pharmacother 1995;29:235-239.
30. Pflugfelder PW, Huff M, Oskalns R, Rudas L, Kostuk WJ. Cholesterol-lowering therapy after heart transplantation: a 12-month randomized trial. J Heart Lung Transplant 1995;14:613-622.
31. Regazzi MB, Iacona I, Campana C, Gavazzi A, Vigano M, Perani G. Clinical efficacy and pharmacokinetics of HMG-CoA reductase inhibitors in heart transplant patients treated with cyclosporine A. Transp Proc 1994;26:2644-2645.
32. Smith PF, Eydelloth RS, Grossman SJ, Stubbs RJ, Schwartz MS, Germershausen JI, Vyas KP, Kari PH, Macdonald JS. HMG-CoA reductase inhibitor-induced myopathy in the rat: cyclosporine A interaction and mechanism studies. J Pharmacol Exp Ther 1991;257:1225-1235.
33. Goldberg RB, Roth D. A preliminary report of the safety and efficacy of fluvastatin for hypercholesterolemia in renal transplant patients receiving cyclosporine. Am J Cardiol 1995;76:107A-109A.
34. Henkin Y, Oberman A, Hurst DC, Segrest JP. Niacin revisited: clinical observations on an important but underutilized drug. Am J Med 1991;91:239-246.